Klaus Veitinger, M.D., Ph.D.

Klaus Veitinger, M.D., Ph.D.

Klaus Veitinger, M.D., Ph.D., is Chairman of Promentis and is currently a Venture Partner with OrbiMed. During his prior 16-year pharmaceutical career, Dr. Veitinger held senior management positions in drug development, licensing and business development, strategic planning and M&A, as well as general management. Most recently Dr. Veitinger was a Member of the Executive Board of Schwarz Pharma AG and the Chief Executive Officer of Schwarz Pharma Inc. with responsibility for the U.S. and Asia businesses culminating in the ultimate sale of the Schwarz Group. Dr. Veitinger has served and currently serves on the boards of several private and public companies in the life sciences sector. For seven years he was a Director of PhRMA. Dr. Veitinger received his M.D. and his Ph.D. from the University of Heidelberg. He earned his MBA at INSEAD in France.


Tim Keane

Tim Keane is President of Keane Consultants, a data analytics firm, a director of First Business Bank (Nasdaq:FBIZ) and an active investor. He is the director of Golden Angels Investors. He was the founder of Retail Target Marketing Systems, now a unit of Fidelity Information Systems (NYSE: FIS) and is a board director of several private equity owned companies.

Daniel Lawton, J.D.

Daniel Lawton
Chief Executive Officer

Daniel Lawton is the Chief Executive Officer of Promentis Pharmaceuticals. Mr. Lawton has more than 20 years of experience in the pharmaceutical and life sciences industry. Previously, Mr. Lawton was Group President at Dohmen Life Sciences, and Vice President and General Counsel of Schwarz Pharma, Inc. where he was also a member of the U.S. senior management group. His previous work experience includes a number of senior positions at Abbott Laboratories supporting its U.S., Canadian, European and Japanese businesses, with a focus on new business development, licensing, acquisitions and related transactions. Mr. Lawton has practiced law at firms in Europe and the United States. He is a graduate of Harvard Law School and was a Teaching Fellow at Harvard University (Economics under Professor Martin Feldstein).

Patrick Schwarz-Schuette

Patrick Schwarz-Schuette

Patrick Schwarz-Schuette began serving on Promentis’ Board in 2009. Mr. Schwarz-Schuette is currently the Managing Director of Black Horse Investments GmbH in Dusseldorf, Germany. Previously, he led Schwarz Pharma AG as Chairman of its Executive Board for more than a decade (1992 to 2006), culminating in the sale of the Schwarz group to UCB in a transaction valued at approximately six billion U.S. Dollars. Before assuming the role of Chairman, Mr. Schwarz-Schuette was a member of the Schwarz Pharma Executive Board (1988 to 1992), and previously led Sanol GmbH as General Manager. Early in his career, Mr. Schwarz-Schuette was a Management Consultant at Booz Allen & Hamilton, and received his diploma in business administration from the University of Hamburg.


Robert Weisskoff, Ph.D.

Robert Weisskoff, Partner, joined F-Prime Capital in 2004. Robert has worked extensively in both academia and the bioscience industry for thirty years. Prior to F-Prime, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of over 100 peer-reviewed scientific papers, and an inventor on 6 US patents.

Robert holds a Ph.D. in Physics from the Massachusetts Institute of Technology and an M.B.A. from Columbia University. He received his A.B. degree in Physics from Harvard University, graduating magna cum laude and Phi Beta Kappa.

Robert serves on the Board of Directors of Caribou Biosciences, CORE Diagnostics, Farapulse, Plasmagen Biosciences, Promentis Pharmaceuticals, ShouTi, Tempest Therapeutics, Trivitron Healthcare, Xilio Therapeutics and Zenflow, Inc. He has previously served on the boards of Accuri Cytometers (acquired by Becton Dickinson), Ikano Therapeutics (acquired by UCB), Laurus Labs (NSE:LAURUSLABS), Surface Oncology (NASDAQ:SURF), Tetraphase (NASDAQ:TTPH), Transave (NASDAQ:INSM), Topaz (acquired by Sanofi Pasteur), and ViewRay (NASDAQ:VRAY).